Type 2 Diabetes – Psoriasis Often Accompanies Obesity and Diabetes

An antidiabetic drug, liraglutide, is in the class of drugs called glucagon-like peptide-1 analogues. Psoriasis, is an inflammatory disease, and is often seen along with Type 2 diabetes, and is also frequently accompanied by obesity.

Liraglutide and other members of its class work to control Type 2 diabetes by moderating the immune system to decrease inflammation and lowering body weight. In an article published in the Journal of European Academy of Dermatology and Veneriology, in June 2012, investigators at St. Vincent’s University Hospital in Dublin, Ireland, looked at the use of liraglutide in people with both psoriasis and diabetes.

It was found when people with both conditions were treated with injections of liraglutide, their weight and blood sugar levels decreased significantly. There was also a slight decrease in white blood cells which are responsible for causing inflammation. Their psoriasis lesions showed improvement, as did their quality of life related to their skin condition.

Liraglutide, also known as Victoza, is a once-a-day injectable medication given for Type 2 diabetes in combination with diet and exercise. It prevents blood sugar levels from going too high for 12 hours after meals by:

  • slowing down the stomach when it empties its food into the small intestine,
  • by increasing production of insulin, and
  • by decreasing the production of glucagon, a hormone that raises blood sugar levels.

It can help the pancreatic beta cells, the cells that produce insulin:

  • to regenerate,
  • decrease appetite, and
  • lower blood fats.

It is injected under the skin once a day, usually in a dose of 1.2 or 1.8 mg. It comes in pre-filled pens designed to be attached to hypodermic needles. Side effects are usually mild, and include abdominal distress and diarrhea. Since it has been associated with some kinds of cancer in rodents, it should only be used when strictly needed. Liraglutide was approved by the US Food and Drug Administration (FDA) in 2010.

Exenatide, also known as Byretta or Bydureon, is another drug in the same class as liraglutide. The long-acting form, Bydureon, was approved by the FDA in January 2012. Byretta is injected under the skin twice a day and Bydureon is injected once weekly. Like liraglutide, it works by increasing insulin levels after meals and slowing the stomach’s emptying. Since it has been linked with thyroid cancer in rats, neither form of exenatide should not be given to anyone with a history of thyroid cancer.

For people with Type 2 diabetes who also suffer from psoriasis and obesity, liraglutide or another glucagon-like peptide-1 analogue might be something to discuss with their doctor.



Source by Beverleigh H Piepers

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.